Immunic gets FDA OK to start Phase 2, 3 MS studies

 Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory Approval -

- Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis (PMS), Designed to Corroborate IMU-838's Neuroprotective Potential and Support Differentiated Profile -

- Company Expects Initiation of Both ENSURE and CALLIPER in the Second Half of 2021 -

- Conference Call and Webcast to be Held July 1, 2021 at 8:00 am ET -

Conference Call and Webcast Information

Immunic's management team will host a public conference call and webcast on July 1, 2021 at 8:00 a.m. Eastern Time to discuss the company's overall MS development strategy, the phase 3 ENSURE program in RRMS, and the phase 2 CALLIPER trial in PMS.

To participate in the conference call, dial 1-877-870-4263 (USA) or 1-412-317-0790 (International) and ask to be joined into the Immunic, Inc. call. A live, listen-only webcast of the conference call can be accessed at https://www.webcaster4.com/Webcast/Page/2301/39951 or on the "Events and Presentations" section of Immunic's website at ir.imux.com/events-and-presentations.

https://finance.yahoo.com/news/immunic-inc-announces-fda-clearance-103000225.html